We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

118 hedge funds and large institutions have $186M invested in Aldeyra Therapeutics in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 24 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 24

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

40% more call options, than puts

Call options by funds: $5.07M | Put options by funds: $3.63M

5% more funds holding

Funds holding: 112118 (+6)

0.69% more ownership

Funds ownership: 61.76%62.45% (+0.69%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less capital invested

Capital invested by funds: $196M → $186M (-$10.8M)

Holders
118
Holders Change
+6
Holders Change %
+5.36%
% of All Funds
1.55%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
24
Increased
39
Reduced
24
Closed
16
Calls
$5.07M
Puts
$3.63M
Net Calls
+$1.44M
Net Calls Change
+$85K
Name Holding Trade Value Shares
Change
Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$878K +$203K +39,658 +29%
Renaissance Technologies
27
Renaissance Technologies
New York
$834K +$306K +59,700 +56%
Millennium Management
28
Millennium Management
New York
$808K +$831K +161,926 New
KCM
29
Kennondale Capital Management
Virginia
$755K +$776K +151,280 New
Charles Schwab
30
Charles Schwab
California
$682K
Two Sigma Investments
31
Two Sigma Investments
New York
$656K -$78.8K -15,349 -10%
N
32
Nuveen
North Carolina
$647K
Two Sigma Advisers
33
Two Sigma Advisers
New York
$625K -$431K -84,000 -40%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$583K -$6.71K -1,308 -1%
TI
35
Trexquant Investment
Connecticut
$571K +$528K +102,980 +895%
SO
36
STRS Ohio
Ohio
$489K
UBS Group
37
UBS Group
Switzerland
$470K +$348K +67,746 +255%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$458K +$330K +64,314 +234%
Citadel Advisors
39
Citadel Advisors
Florida
$427K +$162K +31,491 +58%
HWAM
40
Hennion & Walsh Asset Management
New Jersey
$426K -$8.15K -1,588 -2%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$390K +$5.58K +1,087 +1%
Barclays
42
Barclays
United Kingdom
$376K +$50.1K +9,769 +15%
AQR Capital Management
43
AQR Capital Management
Connecticut
$352K +$362K +70,563 New
IAIM
44
International Assets Investment Management
Florida
$312K -$1.17M -227,537 -79%
HF
45
HRT Financial
New York
$308K +$318K +61,889 New
LPL Financial
46
LPL Financial
California
$297K +$199K +38,702 +186%
AllianceBernstein
47
AllianceBernstein
Tennessee
$293K -$22.3K -4,340 -7%
CIBC Private Wealth Group
48
CIBC Private Wealth Group
Georgia
$263K
AA
49
ALPS Advisors
Colorado
$240K +$13.4K +2,619 +6%
Mackenzie Financial
50
Mackenzie Financial
Ontario, Canada
$238K +$186K +36,160 +311%

ALDX Hedge Fund Activity: Q4 2024 in Review

118 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2024, worth a combined $186M — down 5.5% from $196M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ALDX positions and 16 closed out — a net gain of 8 holders — while 39 added to existing stakes and 24 trimmed.

The largest buyer was Ardsley Advisory Partners, adding an estimated $3.34M. The largest seller was Invesco, cutting an estimated $3.22M.

  • 118 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2024, up from 112 in Q3 2024.
  • Funds reported $186M of Aldeyra Therapeutics stock for Q4 2024, down 5.5% quarter-over-quarter.
  • 24 funds opened new Aldeyra Therapeutics positions in Q4 2024 and 16 closed out, a net change of +8 holders.
  • The largest Aldeyra Therapeutics buyer in Q4 2024 was Ardsley Advisory Partners, an estimated $3.34M added.
  • The largest Aldeyra Therapeutics seller in Q4 2024 was Invesco, an estimated $3.22M sold.

Based on aggregated 13F filings for Q4 2024.